MK 2118

Drug Profile

MK 2118

Alternative Names: MK-2118

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 18 Aug 2017 Merck plans a phase I trial of MK 2118 in combination with pembrolizumab for Solid tumours and Lymphoma (Late-stage disease, Metastasis disease, Monotherapy, Combination therapy) in USA in August 2017 (NCT03249792)
  • 09 Aug 2017 Preclinical trials in Solid tumours (Late-stage disease, Metastatic disease) in USA (Intratumoural) before August 2017 (NCT03249792)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top